INTERIM REPORT OF BIOHIT 1.1.-30.9.2001

BIOHIT PLC.  STOCK EXCHANGE RELEASE  7.11.2001  AT 10:00
INTERIM REPORT OF BIOHIT 1.1.-30.9.2001

The  result of the Biohit Group was positive contrary to the  previous
year  and  totalled MEUR 0.1 (MEUR 0.5 loss 1-9/2000). The  Group  net
sales  totalled  MEUR  18.7. Biohit continued  investing  strongly  in
research  and development, and international marketing. As  a  result,
the  average  number of personnel increased by 36% compared  with  the
previous  year. The net cash flow from operating activities  was  MEUR
1.5 positive.

Net Sales

The  net  sales of the Biohit Group for the reporting period  totalled
MEUR  18.7  (MEUR  16.8), i.e., demonstrating an 11% growth.  The  net
sales  were  generated  primarily by  the  sales  of  liquid  handling
products, their disposable tips as well as maintenance services.

Profit

The  profit  before amortization on goodwill was MEUR 1.3 (MEUR  0.5).
The  operating profit was MEUR 0.5 (MEUR 0.2 loss), and the profit for
the period MEUR 0.1 (MEUR 0.5 loss). The income taxes of MEUR 0.3 have
been  accounted  for on the basis of the profit for  the  period.  The
profitability of the liquid handling business has remained good. This,
on  its part, has rendered possible the investments in the development
of the diagnostics business.

Balance Sheet

The  business  operations of Locus genex Oy,  the  subsidiary  company
specializing in diagnostic products, were transferred to  Biohit  Plc.
on  May  1,  2001. It has been calculated that the dissolution  has  a
positive  corporate  tax impact of MEUR 0.7 on  the  Group,  which  is
deferred  in the consolidated financial statements over the  remaining
amortization  period  of  5 years of the goodwill  relating  to  Locus
genex.  With regard to the dissolution of Locus genex Oy, the  balance
sheet of September 30, 2001 includes a tax liability of MEUR 1.2 under
short-term liabilities and a deferred tax receivable of MEUR 1.2 under
receivables.

Liquidity

The  liquidity of the Biohit Group is good. The net cash flow provided
by  operating activities during the reporting period was approx.  MEUR
1.5  positive. The Group's liquid assets totalled MEUR 2.6 at the  end
of  the period. The equity ratio was 66.7% at the end of the reporting
period.

Investments

The  gross investments of the reporting period totalled MEUR 1.5 (MEUR
5.4).  The  clean room unit enabling the mass production of diagnostic
tests  together  with  related equipment  as  well  as  machinery  and
equipment   intended   for   increasing  other   production   capacity
constituted the major part of the investments.

Personnel

The  average  number  of personnel totalled 285 during  the  reporting
period  (209  during the corresponding period in 2000), of  which  174
were  employed  by the parent company (141 in 2000)  and  111  by  the
subsidiaries  (68  in 2000). The increase in personnel  resulted  from
investments  made  in  2000  in research  &  development,  production,
acquisitions in the U.S. and Russia as well as personnel increases  in
subsidiaries.

The  purpose of these measures is to reinforce the sales and servicing
of  Biohit's  current products as well as to prepare to  commence  the
sales of diagnostic tests, instruments and complete analyzing systems.

Main Events of the Reporting Period

Liquid Handling

In  the  area  of  liquid handling Biohit launched the new  electronic
eLINE  -pipettor range. The first models were introduced  in  February
after  which the launch has continued in Europe, the U.S.,  Japan  and
elsewhere in Asia.

In  the  area  of  liquid handling Biohit was awarded  three  Japanese
patents  (JP  3168296, JP 3215859 and JP 3215860)  and  three  Finnish
patents  (FI  107025,  FI 107026 and FI 107027) during  the  reporting
period.

Diagnostics

In  the  area  of  diagnostics the evaluations of the test  panel  for
determining  Helicobacter pylori -infection and atrophic gastritis  as
well as for screening the risk of gastric cancer and peptic ulcer from
blood  samples  continued (see the enclosure  on  Biohit's  diagnostic
products).  During  the  last  quartal of  the  reporting  period  the
multicenter study covering the cities of Helsinki, Seinäjoki,  Tampere
and  Vantaa continued in Finland. The study began in 2001. The samples
of altogether 204 patients were analyzed during the first phase of the
study. The results were similar to those of the evaluation carried out
at  the  Jorvi  hospital in Finland in 2000 (see  the  Stock  Exchange
Release of Biohit, Oct. 3, 2000).

During  the reporting period evaluations were in progress in  Germany,
the  U.K.  and  Ireland.  One  evaluation  was  completed  during  the
reporting  period  in Italy with good results. On  the  basis  of  the
results  the  evaluation will be extended to a  multicenter  study  in
Italy.  Individual evaluations were carried out in  France  and  Iraq.
Arrangements  for  commencing evaluations in Japan, the  U.S.,  China,
Russia and the Philippines were initiated.

During the reporting period the marketing of the said test panel began
for  research  use  worldwide. In Canada  authorities  issued  product
licenses  for  the  Pepsinogen I, Gastrin-17 and  Helicobacter  pylori
-test  kits  (GastroPanel).  This  enables  Biohit  to  commence   the
marketing  and  sales  of the GastroPanel also  for  clinical  use  in
Canada.  On the basis of this Biohit concluded distribution agreements
for  the diagnostic products with two co-operation partners in Canada.
During the reporting period United Clinical Laboratories commenced the
marketing of the test panel for its clientele in Finland.

In  the  U.K.  Immunology Quality Services evaluated  with  favourable
results  Biohit's  anti-dsDNA ELISA -test kit  for  the  diagnosis  of
systemic  lupus erythematosus (SLE). The evaluation demonstrated  that
the sensitivity, specificity and precision of the test were good.

The European Commission granted Biohit an approx. MEUR 0.2 support for
the   development  of  monoclonal  antibodies  and   test   kits   for
phytoestrogens. The development work commenced in May 2001 and it will
last until April 2004. The work is part of a Europe-wide project,  the
purpose of which is to study the role of dietary phytoestrogens in the
prevention of certain types of cancer.

During   the   reporting  period  the  new  production  premises   for
manufacturing  diagnostic  products  were  finished  at  the  Helsinki
office.  The  premises enable to enter from the  pilot  production  of
diagnostic tests to their mass production.

In order to enhance the evaluation and adoption of its diagnostic test
systems  Biohit  commenced to offer laboratory  services  targeted  to
researchers  and health care. The State Provincial Office of  Southern
Finland, Department for Social and Health Affairs granted a permission
for  the  service  laboratory on May 8, 2001. The  service  laboratory
collects patient samples, e.g., from health care centers, occupational
health service centers, other medical centers as well as regional  and
central  hospitals. The laboratory analyses conducted aim  to  support
basic  research  and promote correct diagnoses and  related  treatment
(see the enclosure).

Finally, the ISO 9001 -quality system certification of Biohit Plc. was
extended  to  cover also the area of diagnostics as a  result  of  the
audit conducted by Det Norske Veritas.

Equity Turnover and Price Development

The  equity  turnover  of Biohit's B-shares  on  the  NM-list  of  the
Helsinki  Exchanges totalled EUR 3,594,974 and the  number  of  shares
traded  604,243 pieces during the reporting period. The highest  price
was EUR 7.20 and the lowest EUR 3.01. The average price was EUR 5.95.

Prospects for 2001

The  net  sales  of  the  Biohit Group for  2001  are  anticipated  to
demonstrate  a growth of approx. 15% compared with the previous  year.
The  result  for 2001 is forecast to be positive although considerable
investments are made in the marketing of the diagnostic product range.
It  is  estimated that diagnostics will begin to generate  significant
sales  only  during  2002. The major part of the net  sales  for  2001
continues to be generated by the sales of liquid handling products and
maintenance services.

The  launch of new liquid handling products has proceeded as expected.
It  is  estimated  that the sales of the said products  and  analyzing
systems   composed  of  liquid  handling  products,  diagnostics   and
instruments  will  provide a stable basis for the growth  of  the  net
sales  and profit in the future. The growth is expected to be enhanced
on  its  part by the fact that also the diagnostic products  meet  the
quality  requirements set by authorities, e.g., in the  EU  area  with
regard  to  the CE-marking. Biohit's quality system was  certified  on
Oct.  22 to conform also with the requirements set by ISO 13845.  This
enables  Biohit to sell its diagnostic tests, in addition for research
use, also to clinical use in the EU-area.

Group Income Statement

                             1-9      1-9                       1-12
                            2001     2000   Change   Change     2000
                            MEUR     MEUR     MEUR        %     MEUR
Net sales                   18.7     16.8      1.9       11     24.3
Operating expenses          16.6     15.3      1.3        8     22.4
Depreciation excluding                                              
 goodwill amortization       0.9      1.0     -0.1      -10      1.4
Amortization on                                                     
 goodwill                    0.7      0.7      0.0        5      1.0
Operating profit/loss        0.5     -0.2      0.7      357     -0.5
Financial expenses                                                  
 (net)                       0.1      0.0      0.1      457      0.1
Profit/loss before                                                  
 extraordinary items         0.4     -0.2      0.6      268     -0.6
Extraordinary income         0.0      0.0      0.0        0      0.3
Profit/loss before                                                  
 taxes                       0.4     -0.2      0.6      268     -0.3
Profit/loss for the                                                 
 period                      0.1     -0.5      0.5      113     -0.6

Group Balance Sheet

                         30.9.2001       30.9.2000      31.12.2000
                      MEUR        %    MEUR       %    MEUR        %
Assets                                                              
Non-current assets    11.3       45    11.3      45    11.3       47
Current assets                                                      
 Inventories           4.2       17     3.7      15     3.8       15
 Receivables           7.0       28     6.7      27     6.5       26
 Cash and cash                                                      
  equivalents          2.6       10     3.3      13     3.0       12
Total assets          25.1      100    25.0     100    24.6      100
                                                                    
Liabilities and                                                     
shareholders'                                                       
equity
Shareholders'                                                       
equity                    
  Share capital        2.2        9     2.2       9     2.1        9
  Share premium                                                     
fund                  14.9       59    14.9      60    14.9       61
  Accumulated                                                       
   profits/losses     -0.6       -2    -0.4      -1    -0.6       -3
  Capital loans        1.2        5     1.1       4     1.1        5
                                                                    
Minority interest      0.1        0     0.1       0     0.1        0
Long-term                                                           
 liabilities           2.3        9     2.1       8     2.8       11
Short-term                                                          
 liabilities           5.0       20     5.0      20     4.2       17
                                                                    
Total liabilities                                                   
and shareholders'
equity                25.1      100    25.0     100    24.6      100

                           1-9/01   1-6/00 Change  Change-%  1-12/00
                                                                    
Investments, gross MEUR       1.5      5.4   -3.9       -72      7.1
                                                                    
Employees, average            285      209     76        36      222

Pledges given, commitments and contingencies

                                 30.9.2001     30.9.2000   31.12.2000
Loans for which pledges               MEUR          MEUR         MEUR
 have been given                                                     
Loans from financial                                                 
 Institutions                          2.1           3.0          2.8
  Corporate mortgages                  3.4           3.4          3.4
                                                                     
Other long-term liabilities            0.8             -          0.8
  Mortgages                            0.8             -          0.8
                                                                     
Leasing commitments                    3.7           4.2          4.2
                                                                     

Interest on Capital Loans

The unrecorded interest accrued on capital loans on September 30, 2001
totalled to MEUR 0.4 and on Dec. 31, 2000 to MEUR 0.4.

                                 30.9.2001     30.9.2000   31.12.2000
Ratios                                                               
  Equity ratio, %                     66.7          67.2         66.9
  Earnings per share, EUR             0.00         -0.04        -0.06
  Shareholders' equity                                               
   per share, EUR                     1.30          1.32         1.30
Average number of shares        12,643,377    12,549,790   12,573,123
Number of shares at the                                              
 end of the period              12,643,377    12,643,377   12,643,377

Derivative Contracts

The Group does not have any off balance sheet financial instruments.

The figures of the Interim Report are unaudited.

Helsinki, November 7, 2001

Board of Directors of Biohit Plc.

Overview on Biohit

Biohit,  operating in the areas of biotechnology and high  technology,
develops,  manufactures  and  markets  liquid  handling  products  and
accessories  as well as diagnostic test systems for use  in  research,
health care and industrial laboratories.

In  the  area of liquid handling Biohit's main products are electronic
and   mechanical  pipettors  and  their  disposable  tips.  Currently,
Biohit's range of electronic and mechanical pipettors is the widest in
the  world.  Biohit  is  also the global market leader  of  electronic
pipettors.

In  the  area of diagnostics Biohit develops, manufactures and markets
test kits based on the enzyme immunoassay (EIA) -method and monoclonal
antibodies  for the screening of different types of disease.  Biohit's
diagnostic  product  range includes, e.g., a  unique  test  panel  for
diagnosing H.pylori -infection and atrophic gastritis as well  as  for
screening  the  risk  of gastric cancer and peptic  ulcer  from  blood
samples, as well as tests for the detection of lactose intolerance and
systemic lupus erythematosus (SLE).

In  order  to  be  able to offer complete analyzing  systems  for  its
customer base, Biohit's product range includes, in addition to  liquid
handling  products and diagnostics, instruments used for the  analysis
of  test results. Moreover, Biohit offers as a part of its product and
marketing  strategy  maintenance, calibration  and  training  services
through the Group companies and distributors.

Biohit's  production plants are located in Kajaani and  Helsinki.  The
sales  and  marketing  subsidiaries are located  in  France,  Germany,
Italy,  Japan,  Russia,  the  U.K. and the U.S.  Biohit's  distributor
network covers altogether approx. 450 members and 70 countries.

Moreover,  many  multinational companies,  such  as  Beckman  Coulter,
Becton  Dickinson,  bioMérieux, Johnson & Johnson  and  3M  complement
their  diagnostic  systems  with Biohit's electronic  liquid  handling
products. As to Group net sales, 96% are generated outside of Finland,
and the degree of domestic production is approx. 95%.

Biohit Plc.

Helena Hentola
Information Resources & Communications


Enclosure: Background on Biohit's Diagnostic Products

Test Panel for Determining Helicobacter pylori -Infection and Atrophic
Gastritis

Australian doctors, Barry J. Marshall and J. Robin Warren isolated the
Helicobacter  pylori  (H.  pylori)  in  1982.  This  bacterium   lives
protected  from gastric acids on the mucous membrane of  the  stomach.
The H. pylori -infection is usually caught in childhood and rarely  in
adulthood.  The infection spreads orally (oral-oral transmission)  and
via  the contents of the stomach (e.g. vomiting) and possibly also via
feces.  If untreated the infection lasts for a lifetime and causes  an
inflammation  of  the  stomach, i.e., gastritis. Gastritis  is  nearly
always  caused  by H. pylori -infection. In a small  number  of  cases
gastritis may develop as a result of an autoimmune disease. Over  half
of  the global population are infected by H. pylori (approx. 3 billion
persons) and related gastritis. In half of the infected cases (approx.
1.5  billion)  the  gastritis develops over the  years  into  atrophic
gastritis, which refers to the inflammation and atrophy of the  mucous
membrane of the stomach.

The isolation of the H. pylori changed the understanding of the causes
of  gastric cancer and peptic ulcer. Today it is known that H.  pylori
-infection and gastritis are nearly always related with gastric cancer
and peptic ulcer. Before 1982, and even for a long time after that, it
was  believed  that peptic ulcer develops primarily  as  a  result  of
hypersecretion of acid, stress and anxiety.

In reality in 70-90% of the cases the primary cause of peptic ulcer is
gastritis or atrophic gastritis caused by H. pylori -infection.  Other
causes are anti-inflammatory analgesics (nsaid drugs) and asperin.  In
1994  a research unit operating under WHO (IARC - International Agency
for  Research  on  Cancer) presented a consensus statement,  based  on
available research results, that gastric cancer is caused by H. pylori
-infection. H. pylori -infection was considered to be related with the
development of gastric cancer (carcinogenity class 1) in a similar way
as  smoking  is  related to lung cancer. According  to  the  consensus
statement H. pylori -infection launches a chain of events, such as the
development  of  atrophic gastritis, which in certain cases  leads  to
gastric cancer.

The  risk  of  gastric  cancer of a patient  suffering  from  atrophic
gastritis of the corpus is 5-fold compared with normal population.  If
both  the corpus and antrum are severely atrophic the risk is  approx.
90-fold. When only the antrum is severely atrophic the risk of gastric
cancer  is approx. 20-fold. In addition, the risk of peptic  ulcer  is
approx. 25-fold compared with normal population. It has been estimated
that  in the U.S. approx. 20 million persons suffer or develop  peptic
ulcer  during  their lifetime. The equivalent amount  in  the  Finnish
population can be estimated to be slightly less than 500 000. Atrophic
gastritis   and  the  early  stage  of  gastric  cancer  are   usually
symptomless  or show only weak symptoms. The surgical  removal  of  an
early  stage  gastric  cancer  is  usually  successful.  However,  the
prognosis of a prolonged cancer case demonstrating symptoms  is  weak;
the  5-year survival rate of those surgically treated is only  10-20%.
The  equivalent survival rate of patients treated early in  which  the
cancer is restricted to the mucosa and submucosa is approx. 90%.

Approx.  30%  of  the  global population,  i.e.,  nearly  two  billion
persons, suffer from dyspepsia, the occasional or continuous  pain  or
discomfort  in  the  upper part of the stomach. The  only  method  for
examining  whether  a patient suffering from dyspepsia  or  H.  pylori
-infection  suffers  from atrophic gastritis has until  now  been  the
histological (microscopic) examination of biopsies taken in connection
with  gastroscopy. As this invasive examination is often uncomfortable
for  the  patient, expensive and its rapid availability  limited,  the
patient is usually treated only on the basis of anamnesis, symptoms or
clinical  examination. Many cases have demonstrated the  unreliability
of  an examination made on the basis of symptoms, which often leads to
incorrect conclusions.

Severe  consequences may result from delays in targeted treatment  and
further  examinations based on a correct diagnosis. Without a  correct
diagnosis  the  treatment may be delayed and the  disease  may  become
impossible  to cure. This, at worst, may increase the risk of  deaths,
decrease the quality of life, and increase human suffering and  health
care costs.

Biohit's GastroPanel and GastroSoft

Biohit  has  developed  and  patented  a  unique  test  panel  (Biohit
GastroPanel),  which enables to determine from a blood sample  whether
the  patient  suffers from gastritis caused by H.  pylori  -infection,
whether the gastritis is atrophic and in which part of the stomach the
changes  are  located.  This  is  done  by  measuring  the  levels  of
Pepsinogen  I and Gastrin-17, and the H. pylori -antibodies  from  the
blood  sample. The test panel enables to identify those patients whose
risk  of  gastric cancer and peptic ulcer have considerably  increased
and,  as a result, need to be directed immediately to gastroscopy  and
the  examination  of  biopsy  samples (see  www.biohit.com/  Sipponen,
Härkönen  and Alanko. Determination of Atrophic Gastritis  from  Serum
Samples,  Finnish  Medical Journal, No. 38/2001, Vol.  56,  pp.  3833-
3839).

The research carried out thus far has demonstrated that the results of
the test panel are in practice equally reliable as those received with
gastroscopy  and  the examination of biopsy samples. This  applies  to
cases when it is necessary to find out whether the mucous membrane  of
the  stomach  is  healthy  or whether it is  inflammated  or  atrophic
(atrophic  gastritis). The research results support the argument  that
Biohit's  test  panel is suitable as an initial and  easy  method  for
examining  dyspeptic  patients. Nearly always a correct  diagnosis  is
reached whether it is a case of a healthy, normally functioning mucous
membrane  of  the  stomach  or  whether it  is  inflammated,  atrophic
(atrophic gastritis) and does not function normally.

Especially  in  cases of younger patients over half of  the  dyspeptic
symptoms  are  functional (functional dyspepsia). These cases  can  be
differentiated from organic symptoms by using Biohit's test panel.  If
the test panel demonstrates that the mucous membrane of the stoamch is
healthy  this  means that the symptoms are most likely functional  and
are  not caused by peptic ulcer. The risk of gastric cancer and peptic
ulcer is very low, nearly nonexistent, if the stomach is healthy.

A  multicenter  study  is carried out currently in  Finland  in  which
gastroscopy  and  biopsy samples of altogether 204 patients  suffering
from dyspepsia were examined. The results demonstrated that the mucous
membrane  of  111  patients was normal, and only 20 patients  suffered
from  advanced  atrophic gastritis. When the blood  samples  of  these
patients  were examined with Biohit's test panel, the result  was  the
same. The mucous membrane of the stomach of 73 patients was healthy or
its  surface was mildly inflammated (gastritis). Such patients do  not
have  an  immediate need for gastroscopy or the examination of  biopsy
samples  for  confirming the results of the test panel if the  patient
does  not  suffer,  e.g.,  from reflux disease,  inflammation  of  the
esophagus, use analgesics, have an exceptionally high cancer risk,  or
if  the dyspeptic patient is not over 45 years. On the basis of  these
examinations it can be concluded that less than 10% of those examined,
i.e.,  20 persons out of 204, would have needed, on the basis  of  the
results produced by the test panel, gastroscopy and examination of the
biopsy  samples  immediately due to gastritis and  related  risks  and
possible diseases.

For  the  interpretation of the results of the test panel  Biohit  has
developed  an  easy-to-use  computer program,  Biohit  GstroSoft  (the
program  can  be  tested  at www.biohit.com).  On  the  basis  of  the
laboratory  results  the program draws up a recommended  diagnosis  of
possible  H.  pylori -infection and atrophic gastritis. Moreover,  the
program  indicates  the patient's risk of gastric  cancer  and  peptic
ulcer  compared  with normal population. The program further  gives  a
recommendation  based  on  the  Maastricht  2000  -consensus   whether
eradication therapy of H. pylori -infection is necessary as well as an
instruction whether gastroscopy, examination of biopsy samples and the
measurement  of  the  levels  of  vitamin  B12  and  homocysteine  are
necessary.

Vitamin B12 and Homocysteine

Atrophic  gastritis  of the corpus caused by H. pylori  -infection  or
autoimmune  disease result in the malabsorption of  vitamin  B12.  The
deficiency  of vitamin B12 causes an increase of homocysteine  in  the
body.  Homocysteine  is  an intermediate product  of  metabolism.  The
increased level of homocysteine in blood and tissues signal a  serious
disturbance  of methionine metabolism in the cells. The deficiency  of
vitamin  B12 is related, e.g., with dementia, depression,  damages  of
the  peripheral  nervous  system, and  increases  the  risk  of  these
diseases (see www.b12.com). An increased level of homocysteine in  the
body  increases  the  risk of arteriosclerosis  and  heart  and  brain
strokes (see www.homocysteine.com).

Humans  and  other  mammals  gain  the  necessary  vitamin  B12   from
nutrition. The reason is that only micro-organisms are able to produce
the  said  vitamin.  The  absorption of vitamin  B12  from  the  small
intestine requires a healthy, normally functioning mucous membrane  of
the  corpus.  Those  patients suffering from atrophic  gastritis  need
substitute treatment for vitamin B12 (e.g. an injection of vitamin B12
at three months' intervals).

The  deficiency  of  vitamin B12 in the body is an  increasing  health
problem worldwide, especially concerning the elderly. Approx. 5-15% of
the  elderly suffer from diseases caused by the deficiency of  vitamin
B12.  Available research results indicate that a significant  part  of
the  patients suffering from the deficiency of vitamin B12  are  those
whose  deficiency has resulted from the malabsorption of  vitamin  B12
caused by atrophic gastritis. An observation, which needs to be  taken
seriously,  is  that  the damages of the brain tissue  and  peripheral
nervous  system  (dementia,  depression  etc.)  are  irreversible  and
develop  already years before the anemia caused by the  deficiency  of
vitamin B12 occurs.

Biohit's Test Panel Promotes Targeted Diagnoses and Treatment as  well
as Prevention of Diseases

Biohit's  GastroPanel and related GastroSoft are well suited  for  the
use  of general practitioners and specialists for diagnosing H. pylori
-infection and atrophic gastritis as well as for screening the risk of
gastric  cancer and peptic ulcer from blood samples. Although atrophic
gastritis  is  a  serious  disease it usually  remains  unnoticed  and
"underdiagnosed". One reason is, most likely, that the  only  reliable
means   thus  far  to  diagnose  atrophic  gastritis  has   been   the
histological  (microscopic) examination of  biopsy  samples  taken  in
connection with gastroscopy. The early diagnosis and correct treatment
of atrophic gastritis prevents many of the diseases described above.

The  test panel enables to determine whether the disease of a  patient
suffering  from  dementia,  depression or heart  or  brain  stroke  is
related with atrophic gastritis of the mucous membrane of the stomach.
The  rapid  and early diagnosis of this connection is most  important.
The  contributing  or primary causes of the disease related  with  the
stomach  can  be eliminated, e.g., by eradication therapy  of  the  H.
pylori   -infection.  When  also  the  levels  of  vitamin   B12   and
homocysteine are determined as a part of the test panel it is possible
to  assess  the risks related with diseases of the nervous system  and
blood  vessels.  This,  on its part, enables, e.g.,  to  commence  the
preventive vitamin B12 substitute treatment.

Approx.  one  third of the global population suffers  from  dyspepsia.
Over half of the cases are functional and only a small part is related
with organic diseases. The test panel is an economic and easy means to
differentiate  between cases of functional dyspepsia and  more  severe
diseases caused by atrophic gastritis.

Since over half of the world population are infected by H. pylori, and
as  half  of these cases lead to atrophic gastritis, justified grounds
exist  to  the  routine use of the test panel in a similar  manner  as
measuring blood pressure and cholesterol and analyzing blood count.

The  H.  pylori -infection is diagnosed worldwide by using serological
tests, breath tests and antigen tests of the feces. These tests enable
to diagnose only whether the patient is infected or not. Biohit's test
panel  makes a major contribution to these tests. On the basis of  the
results  received  so  far  only the test panel  enables  to  diagnose
gastritis, its severity and quality nearly as well as with gastroscopy
and  the examination of biopsy samples. On the otherhand, however, the
tests conducted with the panel (levels of Pepsinogen I and Gastrin-17)
enable  to  assess the condition and functioning of the entire  mucous
membrane  of  the  stomach.  As  the severity  of  atrophic  gastritis
increases,  the  condition  and functioning  of  the  mucous  membrane
weakens.  Atrophic  gastritis cannot be  diagnosed  on  the  basis  of
gastroscopy   but  it  is  necessary  to  study  the  biopsy   samples
histologically.  It must also be noted that, on the  basis  of  a  few
biopsies,  it is not possible to assess the condition and  functioning
of the entire mucous membrane of the stomach.

Biohit's Service Laboratory

In  August  2001  Biohit commenced to offer paid laboratory  services,
which  received  a  permission from the  State  Provincial  Office  of
Southern Finland, Department for Social and Health Affairs on  May  8,

2001.  The  purpose  of the service laboratory is to  collect  patient
samples,  first  in Finland and later in Biohit's subsidiaries,  e.g.,
from  health care centers, occupational health service centers,  other
medical  centers  as well as regional and central hospitals.  Biohit's
test  panel  will be used to determine the Pepsinogen  I  and  II  and
Gastrin-17 concentrations and H. pylori -antibodies from blood samples
(Biohit's test panel). Moreover, the concentrations of vitamin B12 and
homocysteine will be determined as well as telomere DNA antibodies for
the  diagnosis of systemic lupus erythematosus (SLE). In addition, the
biopsies taken in connection with gastroscopy will be used to diagnose
lactose  intolerance  and  carry out further  examinations,  e.g.,  to
confirm  the  diagnosis of gastric cancer and peptic  ulcer.  Biohit's
service laboratory will also engage in the research and development of
diagnostic tests and the analysis of different types of patient data.

The   purpose  of  Biohit's  service  laboratory  is  to  promote  the
diagnostic tests and analyzing systems and, as a result, to  encourage
the  users  of laboratory services provided by Biohit and  other  paid
service  laboratories to commence themselves laboratory  testing  with
analyzing  systems purchased from Biohit. This serves as  a  means  to
promote decentralized laboratory diagnostics, which is performed close
to  the  doctor and patient. This, on its part, is a prerequisite  for
time  and cost savings in reaching correct diagnoses and related rapid
and highly specific treatment (evidence based medicine).

Analyses for Tests Performed by Biohit's Service Laboratory

- GastroPanel:
1)Helicobacter pylori IgG (S-HepyAbG),
  Pepsinogen I (S-Pepsin1), Gastrin-17
 (S-Gastr17-S)
2)S-HepyAbG, S-Pepsin1, S-Pepsin2,
  S-Gastr17-S
- Vitamin B12, fS-B12-vit, KL 1137
- Folat, fS-Folaat, KL 1416
- Folate from erythrocytes, fE-Folaat, KL1414
- Homocysteine, S-Hcyst, KL 1868
- Telomere-DNA IgG-antibodies, S-dsDNAAb
- Celiac panel: Gliadin IgA and IgG, Tissue transglutaminase IgA,
S-AGAAbA KL 3399, S-AGAAbG KL 3400, S-tTGAbA KL 1885
- Determination of lactase and saccharase from biopsies of the small
intestine, Ts-Laktaas, KL 2182, Ts-Sakraas, KL 2601 (1.1.2002)
- Microscopic examination of the endoscopic biopsy samples of the
gastrointestinal tract, Ts-PADGast, KL 4043

The  results of the GastroPanel are analyzed with Biohit's GastroSoft-
program (www.biohit.com). The program functions and is allowed  to  be
used only in connection with Biohit's test panel. The program is based
on  analyses made with Biohit's tests. Comments on the use and further
development of the program can be sent via the Contact us -form  found
under  GastroSoft at www.biohit.com. Instructions for  taking  samples
and delivering the samples to the service laboratory can be gained  at
Biohit Plc, marianne.niemela@biohit.com, fax. +358-9-77386200 or  tel:
+358-9-773 861/Marianne Niemelä.

Additional information:  Osmo Suovaniemi, President & CEO, tel: +358-9-
                         773  861, direct: +358-9-773 86 250,  mobile:
                         +358-40 745 5605, fax: +358-9-773 86 205.

                         http://www.biohit.com

Distribution:            The Helsinki Exchanges
                         The Financial Supervisory Authority
                         Press


Subscribe